T. Rowe Price Associates
RXRX icon

T. Rowe Price Associates’s Recursion Pharmaceuticals RXRX Stock Holding History

T. Rowe Price Associates’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Buy
720,097
+159,351
+28% +$531K ﹤0.01% 1880
2026
Q1 		$1.72M Buy
560,746
+145,383
+35% +$562K ﹤0.01% 1891
2025
Q4 		$1.7M Buy
415,363
+96,479
+30% +$478K ﹤0.01% 1825
2025
Q3 		$1.56M Buy
318,884
+37,217
+13% +$195K ﹤0.01% 1849
2025
Q2 		$1.43M Buy
281,667
+57,433
+26% +$282K ﹤0.01% 1808
2025
Q1 		$1.19M Buy
224,234
+92,244
+70% +$672K ﹤0.01% 1869
2024
Q4 		$893K Buy
131,990
+19,552
+17% +$131K ﹤0.01% 2021
2024
Q3 		$741K Buy
112,438
+24,323
+28% +$174K ﹤0.01% 2089
2024
Q2 		$661K Buy
88,115
+26,050
+42% +$227K ﹤0.01% 2070
2024
Q1 		$619K Buy
62,065
+5,501
+10% +$61.3K ﹤0.01% 2124
2023
Q4 		$558K Buy
56,564
+3,589
+7% +$25.6K ﹤0.01% 2130
2023
Q3 		$406K Sell
52,975
-23,851
-31% -$238K ﹤0.01% 2213
2023
Q2 		$574K Buy
76,826
+2,033
+3% +$14.2K ﹤0.01% 2058
2023
Q1 		$499K Sell
74,793
-1,126
-1% -$8.93K ﹤0.01% 2107
2022
Q4 		$585K Buy
75,919
+39,713
+110% +$389K ﹤0.01% 2061
2022
Q3 		$386K Buy
36,206
+13,406
+59% +$136K ﹤0.01% 2260
2022
Q2 		$186K Sell
22,800
-539,390
-96% -$3.61M ﹤0.01% 2625
2022
Q1 		$4.03M Sell
562,190
-295,383
-34% -$3.14M ﹤0.01% 1499
2021
Q4 		$14.7M Buy
857,573
+276,903
+48% +$5.21M ﹤0.01% 1342
2021
Q3 		$13.4M Sell
580,670
-2,415
-0.4% -$68.4K ﹤0.01% 1387
2021
Q2 		$21.3M Buy
+583,085
New +$17.3M ﹤0.01% 1288

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

T. Rowe Price Associates's RXRX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Recursion Pharmaceuticals (RXRX) stake by 28% in Q2 2026, buying an estimated $531K and bringing the position to 720,097 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1880.

T. Rowe Price Associates first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $21.3M in Q2 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • T. Rowe Price Associates held 720,097 shares of Recursion Pharmaceuticals worth $2.64M as of Q2 2026.
  • T. Rowe Price Associates bought 159,351 Recursion Pharmaceuticals shares in Q2 2026, an estimated $531K.
  • Recursion Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1880 holding.
  • T. Rowe Price Associates first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Recursion Pharmaceuticals position peaked at $21.3M in Q2 2021.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.